Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342, 1432–1433 (2013).
Google Scholar
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
Google Scholar
Wellenstein, M. D. & de Visser, K. E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48, 399–416 (2018).
Google Scholar
Kim, T. K., Vandsemb, E. N., Herbst, R. S. & Chen, L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529–540 (2022).
Google Scholar
Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345–359 (2021).
Google Scholar
Chen, L. & Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015).
Google Scholar
Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274–278 (2020).
Google Scholar
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
Google Scholar
Lewis, S. M., Williams, A. & Eisenbarth, S. C. Structure and function of the immune system in the spleen. Sci. Immunol. 4, eaau6085 (2019).
Google Scholar
Bronte, V. & Pittet, M. J. The spleen in local and systemic regulation of immunity. Immunity 39, 806–818 (2013).
Google Scholar
Steenbrugge, J., De Jaeghere, E. A., Meyer, E., Denys, H. & De Wever, O. Splenic hematopoietic and stromal cells in cancer progression. Cancer Res. 81, 27–34 (2021).
Google Scholar
Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl Acad. Sci. USA 109, 2491–2496 (2012).
Google Scholar
Tavukcuoglu, E. et al. Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer. Eur. J. Immunol. 50, 2067–2074 (2020).
Google Scholar
Ugel, S. et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2, 628–639 (2012).
Google Scholar
Iwai, Y., Terawaki, S. & Honjo, T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17, 133–144 (2005).
Google Scholar
Prestipino, A. et al. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med. 10, eaam7729 (2018).
Google Scholar
Getts, D. R. et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J. Immunol. 187, 2405–2417 (2011).
Google Scholar
Allen, B. M. et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat. Med. 26, 1125–1134 (2020).
Google Scholar
Ordikhani, F. et al. Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. JCI Insight 3, e122700 (2018).
Google Scholar
Ouyang, B. et al. The dose threshold for nanoparticle tumour delivery. Nat. Mater. 19, 1362–1371 (2020).
Google Scholar
Gualdrón-López, M. et al. Multiparameter flow cytometry analysis of the human spleen applied to studies of plasma-derived EVs from Plasmodium vivax patients. Front. Cell. Infect. Microbiol. 11, 596104 (2021).
Google Scholar
Anderson, H. L., Brodsky, I. E. & Mangalmurti, N. S. The evolving erythrocyte: red blood cells as modulators of innate immunity. J. Immunol. 201, 1343–1351 (2018).
Google Scholar
Huang, Y. et al. Development of a highly-efficient erythrocyte-drug covalent conjugation platform and its use in treating thrombotic disorders. Cell Res. 33, 887–890 (2023).
Google Scholar
Liu, Y. et al. Developing an erythrocyte‒MHC-I conjugate for cancer treatment. Cell Discov. 10, 99 (2024).
Google Scholar
Behrens, C. R. & Liu, B. Methods for site-specific drug conjugation to antibodies. mAbs 6, 46–53 (2014).
Google Scholar
Geuijen, C. et al. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat. Commun. 12, 4445 (2021).
Google Scholar
Kurino, T. et al. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. J. Immunother. Cancer 8, e000400 (2020).
Google Scholar
Arlauckas, S. P. et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. 9, eaal3604 (2017).
Google Scholar
Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8–19 (2011).
Google Scholar
Canfield, S. M. & Morrison, S. L. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J. Exp. Med. 173, 1483–1491 (1991).
Google Scholar
Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. mAbs 9, 767–773 (2017).
Google Scholar
Lou, B. et al. Preclinical characterization of GLS-010 (zimberelimab), a novel fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Front. Oncol. 11, 736955 (2021).
Google Scholar
Stackhouse, M. et al. Abstract B81: efficacy of nivolumab, pembrolizumab, and atezolizumab against MC38 colon cancer expressing human PD-1 in transgenic C57BL/6 mice expressing human PD-1 and PD-L1 checkpoint genes. Cancer Immunol. Res. 8, B81–B81 (2020).
Google Scholar
Straat, M., van Bruggen, R., de Korte, D. & Juffermans, N. P. Red blood cell clearance in inflammation. Transfus. Med. Hemother. 39, 353–361 (2012).
Google Scholar
Byrnes, J. R. & Wolberg, A. S. Red blood cells in thrombosis. Blood 130, 1795–1799 (2017).
Google Scholar
Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).
Google Scholar
Alshetaiwi, H. et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol. 5, eaay6017 (2020).
Google Scholar
Martínez-Lostao, L., Anel, A. & Pardo, J. How do cytotoxic lymphocytes kill cancer cells? Clin. Cancer Res. 21, 5047–5056 (2015).
Google Scholar
Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).
Google Scholar
Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018).
Google Scholar
Nagaraj, S. et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13, 828–835 (2007).
Google Scholar
Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562–567 (2003).
Google Scholar
Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687–695 (2014).
Google Scholar
Levy, L. et al. Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. Oncoimmunology 4, e998469 (2015).
Google Scholar
van Vugt, M. J. H. et al. Immunogenicity of pembrolizumab in patients with advanced tumors. J. Immunother. Cancer 7, 212 (2019).
Google Scholar
Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286–4293 (2015).
Google Scholar
Weber, J. et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol. Res. 4, 345–353 (2016).
Google Scholar
Valpione, S. et al. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer 1, 210–221 (2020).
Google Scholar
Cai, T., Liu, H., Zhang, S., Hu, J. & Zhang, L. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy. J. Nanobiotechnology 19, 389 (2021).
Google Scholar
Melero, I. et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509–524 (2014).
Google Scholar
Meyer, C. et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247–257 (2014).
Google Scholar
Koh, J. et al. MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. Eur. J. Immunol. 50, 1810–1819 (2020).
Google Scholar
Chen, H. M. et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J. Clin. Invest. 128, 5647–5662 (2018).
Google Scholar
Xue, G. et al. Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells. Nat. Biomed. Eng. 5, 1306–1319 (2021).
Google Scholar
van Cromvoirt, A. M. et al. Donor age and red cell age contribute to the variance in Lorrca indices in healthy donors for next generation ektacytometry: a pilot study. Front. Physiol. 12, 639722 (2021).
Google Scholar
Rab, M. A. E. et al. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. Am. J. Hematol. 94, 575–584 (2019).
Google Scholar
Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Brit. Med. J. 340, c332 (2010).
Google Scholar
Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010).
Google Scholar
Rahim, M. K. et al. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186, 1127–1143 (2023).
Google Scholar
Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978–985 (2018).
Google Scholar
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
Google Scholar
McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329–337 (2019).
Google Scholar
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 (2018).
Google Scholar
Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485–498 (2021).
Google Scholar
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16, 284–287 (2012).
Google Scholar
Keenan, B. P. et al. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis. Cell Rep. 40, 111384 (2022).
Google Scholar
Zheng, Y. et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat. Commun. 11, 6268 (2020).
Google Scholar
Nie, X. et al. Source data for Extended Data Fig. 2d from “Erythrocyte–anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PD-L1: preclinical characterization and results of a phase 1 trial”. figshare https://doi.org/10.6084/m9.figshare.30797153 (2025).
Yao, X. & Gao, X. GaoXlab/aPD1_Ery_scripts: v1. Zenodo https://doi.org/10.5281/zenodo.17797265 (2025).
